Glimixia-VM1 Tablet ER
Glimixia-VM1 Tablet ER
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Cheaper alternative availability
Already at the Best Price
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
About This Medicine
Product description & overview
Glimixia-VM1 Tablet ER is a combination oral antidiabetic medication formulated with Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, designed for extended-release administration. This triple-action formulation targets multiple pathophysiological defects in type 2 diabetes mellitus to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, improving insulin sensitivity without causing hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, attenuating postprandial hyperglycemia. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glimixia-VM1 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled by monotherapy or dual therapy. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. This combination therapy should be used under medical supervision to optimize efficacy and minimize adverse effects.
Active composition
Glimepiride 1 mg
+2 more active ingredients
About Glimepiride
Glimepiride is an oral hypoglycemic agent used to manage blood sugar levels in patients with type 2 diabetes mellitus. It works by stimulating the pancreas to release more insulin, thereby lowering blood glucose levels and preventing the symptoms associated with diabetes. Glimepiride is often prescribed alongside diet and exercise to enhance glycemic control and reduce the risk of diabetes-related complications, such as kidney damage and neuropathy. In summary, Glimepiride is an essential medication for controlling blood sugar levels in type 2 diabetes patients.
How It Works
Glimepiride stimulates insulin secretion from pancreatic beta cells and enhances insulin sensitivity in peripheral tissues, facilitating glucose uptake and lowering blood sugar levels.
All Active Ingredients
Voglibose
Voglibose inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and absorption, thus lowering postprandial glucose levels.
Metformin
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Dosage & How to Use
Dosage information not available. Please consult your doctor or pharmacist.
Safety Advice
Important precautions
Side Effect Occurrence
Based on clinical trials and patient reports.
Overall Tolerance
Most patients tolerate well
Common Side Effects
Safety Advice
Alcohol
It is unsafe to consume alcohol with Glimixia-VM1 Tablet ER.
High Risk
Pregnancy
Glimixia-VM1 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Driving
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Exercise Caution
Liver
Glimixia-VM1 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Glimixia-VM1 Tablet ER may be needed. Please consult your doctor. Glimixia-VM1 Tablet ER is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
Regular Checkup
Breastfeeding
Glimixia-VM1 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Kidney
Glimixia-VM1 Tablet ER is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor. Use of Glimixia-VM1 Tablet ER is, however, not recommended in patients with severe kidney disease.
Regular Checkup
Customer Reviews
0 reviews for Glimixia-VM1 Tablet ER
